Pacer Advisors Inc. increased its holdings in Chemours Company (The) (NYSE:CC) by 16.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,380 shares of the specialty chemicals company’s stock after acquiring an additional 4,257 shares during the period. Pacer Advisors Inc.’s holdings in Chemours Company (The) were worth $1,487,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Financial Architects Inc lifted its stake in Chemours Company (The) by 1,230.3% in the 2nd quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company’s stock worth $111,000 after acquiring an additional 2,719 shares in the last quarter. Acrospire Investment Management LLC raised its stake in shares of Chemours Company (The) by 3.4% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,076 shares of the specialty chemicals company’s stock worth $117,000 after purchasing an additional 100 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its stake in shares of Chemours Company (The) by 2,138.8% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 3,112 shares of the specialty chemicals company’s stock worth $118,000 after purchasing an additional 2,973 shares in the last quarter. Gamco Investors INC. ET AL purchased a new stake in shares of Chemours Company (The) during the 3rd quarter worth about $202,000. Finally, Aull & Monroe Investment Management Corp purchased a new stake in shares of Chemours Company (The) during the 3rd quarter worth about $204,000. 74.04% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/21/chemours-company-the-cc-shares-bought-by-pacer-advisors-inc.html.

Shares of Chemours Company (NYSE CC) traded down $0.57 during midday trading on Tuesday, hitting $51.93. The stock had a trading volume of 1,743,300 shares, compared to its average volume of 2,728,926. The company has a debt-to-equity ratio of 5.07, a quick ratio of 1.63 and a current ratio of 2.19. The firm has a market cap of $9,650.00 and a price-to-earnings ratio of 18.62. Chemours Company has a fifty-two week low of $20.76 and a fifty-two week high of $58.08.

Chemours Company (The) (NYSE:CC) last issued its quarterly earnings data on Thursday, November 2nd. The specialty chemicals company reported $1.12 EPS for the quarter, beating the Zacks’ consensus estimate of $1.01 by $0.11. The business had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.59 billion. Chemours Company (The) had a return on equity of 116.80% and a net margin of 4.86%. The firm’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.61 EPS. analysts predict that Chemours Company will post 3.73 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Monday, November 20th will be issued a dividend of $0.03 per share. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.23%. The ex-dividend date of this dividend is Friday, November 17th. Chemours Company (The)’s dividend payout ratio is 8.28%.

In other Chemours Company (The) news, SVP David C. Shelton sold 5,908 shares of the firm’s stock in a transaction that occurred on Friday, October 13th. The stock was sold at an average price of $56.01, for a total value of $330,907.08. Following the sale, the senior vice president now owns 47,356 shares of the company’s stock, valued at approximately $2,652,409.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider E Bryan Snell sold 13,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $49.35, for a total value of $641,550.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 76,520 shares of company stock worth $4,008,293. 1.14% of the stock is currently owned by insiders.

A number of equities research analysts have recently weighed in on the company. UBS AG raised Chemours Company (The) from a “sell” rating to a “neutral” rating and raised their price target for the stock from $36.00 to $50.00 in a research note on Monday, August 7th. J P Morgan Chase & Co raised their price target on Chemours Company (The) to $55.00 and gave the stock an “overweight” rating in a research note on Friday, August 4th. Citigroup Inc. raised their price target on Chemours Company (The) from $45.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, August 4th. Jefferies Group LLC raised their price target on Chemours Company (The) to $60.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, Zacks Investment Research downgraded Chemours Company (The) from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 12th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $53.89.

Chemours Company (The) Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.